A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or - refractory ovarian, fallopian tube, or primary peritone
|Effective start/end date||1/1/17 → 2/28/25|
- NRG ONCOLOGY FOUNDATION, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.